![Mark Byrne](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ursprung des Netzwerks ersten Grades von Mark Byrne
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
OcuMedic, Inc.
![]() OcuMedic, Inc. Medical SpecialtiesHealth Technology OcuMedic, Inc. manufactures lens equipment. The company was founded by Mark Byrne and Paul Byrne and is headquartered in Mullica Hill, NJ.
1
| Holding Company | Medical Specialties | 1 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Mark Byrne
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
San Jose State University | College/University | Undergraduate Degree | |
Pepperdine University | College/University | Masters Business Admin | |
DiaKine Therapeutics, Inc.
![]() DiaKine Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology DiaKine Therapeutics, Inc. is a start-up biopharmaceutical company developing new, proprietary drugs for unmet medical needs in diabetes and complications related to diabetes. These drugs have the potential to restate the diabetes market by stopping the progression of diabetes and reversing damage already caused by the disease. Because of their unique immune modulating and anti-inflammatory properties, these therapies may potentially benefit people with type 1 and type 2 diabetes and represent a total available market opportunity of approximately $13 billion. The Company's lead compound, Lisofylline (LSF), has had an excellent safety profile in clinical trials to date. LSF works at the cellular level by improving the function of insulin producing islet cells and protecting them from damage and premature death caused when the body's immune system turns on itself. This autoimmune action is the cause of type 1 diabetes and Latent Autoimmune Diabetes in Adults (LADA), which combined affect approximately three million people in the U.S. About three million people with type 2 diabetes use insulin due to diminished insulin production and an increasing resistance to insulin. A primary focus of DiaKine's research and development is on its next generation of orally bioavailable immune modulators which have an improved spectrum of action to LSF. Two such compounds, DT22669 and DT23552, have been identified for further development and are examples of the extensive library of analogs and new structures in its patent portfolio that await discovery for future indications. | Pharmaceuticals: Major | Chief Executive Officer | |
PARADIGM MEDICAL INDUSTRIES, INC. | Medical Specialties | Director/Board Member | |
Humphrey Instruments, Inc. | President | ||
Pennsylvania College of Optometry | College/University | Director/Board Member | |
GUIDED THERAPEUTICS, INC. | Medical Specialties | Founder | |
Freedom Meditech, Inc.
![]() Freedom Meditech, Inc. Medical SpecialtiesHealth Technology Freedom Meditech, Inc. operates as a medical device company which focuses on the development and commercialization of ophthalmic medical devices. It specializes in devices for the detection, monitoring, and management of chronic diseases, such as diabetes. The company was founded by Craig H. Misrach and Keith D. Ignotz in December 2006 and is headquartered in San Diego, CA. | Medical Specialties | Founder |
Statistik
International
Vereinigte Staaten | 10 |
Sektoral
Health Technology | 5 |
Consumer Services | 4 |
Finance | 2 |
Operativ
President | 5 |
Director/Board Member | 4 |
Chief Executive Officer | 2 |
Founder | 2 |
Undergraduate Degree | 1 |
Am stärksten vernetzte Beziehungen
Insiders | |
---|---|
Keith D. Ignotz | 10 |
- Börse
- Insiders
- Mark Byrne
- Unternehmensverbindungen